Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 15,303.10 +8.60 0.06%
S&P 500 1,649.60 -0.91 -0.06%
Nasdaq 3,459.14 -0.27 -0.01%
Ticker Volume Price Price Delta
STOXX 50 2,764.29 -12.49 -0.45%
FTSE 100 6,654.34 -42.45 -0.63%
DAX 8,305.32 -46.66 -0.56%
Ticker Volume Price Price Delta
Nikkei 14,612.50 +128.47 0.89%
Hang Seng 22,618.70 -51.01 -0.23%
S&P/ASX 200 4,983.50 -78.95 -1.56%
  • Fund Type: Closed-End Fund
  • Objective: Sector Fund-Health & Biotech
  • Asset Class: Equity
  • Geographic Focus: U.S.

H&Q Life Sciences Investors

+ Add to Watchlist

XHQLX:US

18.24 USD 0.02 0.11%

As of 09:29:30 ET on 05/24/2013.

Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Snapshot for H&Q Life Sciences Investors (XHQLX)

Year To Date: +26.27% 3-Month: +17.42% 3-Year: +28.75% 52-Week Range: 14.15 - 18.88
1-Month: +5.87% 1-Year: +35.76% 5-Year: +13.94% Beta vs NBI: 0.83

Mutual Fund Chart for XHQLX

No chart data available.
  • XHQLX:US 18.24
  • 1M
  • 1Y
Interactive XHQLX Chart

Previous Close

Fund Profile & Information for XHQLX

H&Q Life Sciences Investors is a diversified, closed-end management investment company incorporated in the USA. The Fund's objective is long-term capital appreciation. The Fund invests mainly in securities of life sciences companies. The Fund invests primarily in securities of public and private companies that are believed to have significant potential for above-average growth.

Inception Date: 05-08-1992 Telephone: 1-617-772-8500
Managers: DANIEL R OMSTEAD
Web Site: www.teklacap.com

Fundamentals for XHQLX

NAV (on 2013-05-24) 18.24
Assets (M) (on 2013-05-24) 268.33
Fund Leveraged N
Minimum Investment 0.00
Minimum Subsequent Investment 0.00

Dividends for XHQLX

Dividend Type Income
Dividend Frequency Quarter
Last Dividend Net (on 2013-05-23) 0.34
Dividend Yield (ttm) 6.85

Fees & Expenses for XHQLX

Front Load 0.00
Back Load 0.00
Current Mgmt Fee 0.98
Redemption Fee 0.00
12b1 Fee 0.00
Expense Ratio 1.72

Top Fund Holdings for XHQLX

Filing Date: 12/31/2012
Name Position Value % of Total
Regeneron Pharmaceuticals Inc 100,799 17,243,685 7.893%
Gilead Sciences Inc 464,770 17,068,678 7.813%
Celgene Corp 179,377 14,120,558 6.464%
Biogen Idec Inc 68,329 10,021,814 4.587%
Alexion Pharmaceuticals Inc 99,214 9,307,265 4.260%
Mylan Inc/PA 279,254 7,673,900 3.513%
Perrigo Co 66,228 6,889,699 3.154%
Puma Biotechnology Inc 342,757 6,426,694 2.942%
Hologic Inc 251,589 5,039,328 2.307%
Vertex Pharmaceuticals Inc 117,332 4,920,904 2.253%

Quotes delayed, except where indicated otherwise. Mutual fund NAVs include dividends. All prices in local currency. Time is ET.

Sponsored Financial Commentaries

Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil